Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call and live audio webcast will follow at 2 PM PT/5 PM ET. The webcast can be accessed on the company's website, with a replay available for 30 days. Allogene focuses on developing AlloCAR T™ products to provide accessible cell therapy for cancer patients. This initiative aims to enhance the reliability and scalability of treatment options.
Allogene Therapeutics (Nasdaq: ALLO) has appointed Stephen L. Mayo, Ph.D., an expert in computational protein design, to its Board of Directors. Mayo has extensive experience in both academia and the biopharmaceutical sector, which is expected to benefit Allogene as it advances its AlloCAR T product pipeline. Mayo's background includes leadership roles at Caltech and co-founding several biotech companies. His appointment is aimed at enhancing the company's ability to deliver innovative cell therapies to cancer patients.
Allogene Therapeutics (Nasdaq: ALLO) announced the FDA granted RMAT designation to ALLO-501A for patients with relapsed/refractory large B cell lymphoma (LBCL). This recognition follows positive results from the ALPHA2 trial, demonstrating safety and durable responses. Treatment initiation occurs within two days, enhancing patient access. The company plans to start a Phase 2 pivotal trial in mid-2022. The RMAT designation aims to expedite the development of ALLO-501A, which aims to meet critical patient needs lacking effective therapies.
Allogene Therapeutics (Nasdaq: ALLO) presented preclinical findings indicating that allogeneic CAR T cells derived from younger, healthy donors exhibit significantly improved fitness and anti-tumor potential compared to those from older donors and cancer patients. This research suggests such cells could mitigate manufacturing failures common in autologous therapies. The study was shared at the 2022 ASGCT Annual Meeting, emphasizing the promise of developing reliable, off-the-shelf CAR T therapies.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has been ranked as the top biotechnology company on the 2022 Best Places to Work list by the San Francisco Business Times and the Silicon Valley Business Journal. This recognition is based on employee surveys evaluating engagement, communication, and team dynamics among other factors, highlighting a strong workplace culture. CEO David Chang emphasized the importance of employee feedback in achieving this accolade. Allogene, which focuses on developing allogeneic CAR T therapies, actively seeks to expand its workforce.
Allogene Therapeutics (NASDAQ: ALLO) updated its corporate progress and financial results for Q1 2022, reporting a net loss of $79.9 million, or $0.56 per share, with cash reserves of $733 million as of March 31, 2022. The pivotal Phase 2 ALPHA2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma is anticipated to commence mid-2022, supported by the newly operational Cell Forge 1 manufacturing facility, capable of producing approximately 20,000 doses annually. The company also received FDA Orphan Drug Designation for ALLO-605, its first TurboCAR product candidate for multiple myeloma.
Allogene Therapeutics has appointed Susan Lundeen as the new Chief People Officer, effective May 2, 2022, in a role designed to enhance their human resources strategy as the company prepares for pivotal trials and expands its AlloCAR T pipeline. Lundeen brings extensive experience from previous roles at Unity Biotechnology and Kythera Biopharmaceuticals. Allogene, a leader in allogeneic cell therapy, currently employs over 320 staff and aims to foster a competitive and inclusive workforce to drive its growth trajectory in cancer treatment.
Allogene Therapeutics (Nasdaq: ALLO) will announce its first-quarter 2022 financial results on May 4, 2022, after market close. Following the announcement, a live audio webcast and conference call will take place at 2:00 PM PT/5:00 PM ET. The webcast can be accessed on the company’s website under the Investors tab, with a replay available for 30 days. Allogene focuses on developing allogeneic CAR T products for cancer treatment, aiming to provide accessible and reliable therapies.
Allogene Therapeutics has received orphan-drug designation from the FDA for ALLO-605, a next-generation AlloCAR T product targeting BCMA for multiple myeloma treatment. This designation follows the Fast Track designation granted in Q2 2021, highlighting ALLO-605's potential to meet unmet medical needs for patients with relapsed/refractory multiple myeloma. The Phase 1 IGNITE trial is currently ongoing, with clinical updates expected by late 2022. The orphan-drug designation includes development incentives like tax credits and user fee exemptions, facilitating the pathway towards FDA approval.
Allogene Therapeutics has unveiled its new 136,000-square-foot cGMP manufacturing facility, Cell Forge 1, in Newark, California. The facility is operational and prepares for the pivotal trial of ALLO-501A targeting relapsed/refractory Non-Hodgkin Lymphoma. Designed for flexibility, it supports clinical trials and potential commercial production of AlloCAR T™ products. The facility prioritizes sustainability, fully powered by renewable energy, aiming for LEED Gold certification. This initiative is significant as Allogene expands its pipeline and regulatory filings while enhancing manufacturing capabilities.